Curis to Present at 20th Annual Needham Virtual Healthcare Conference
Curis, a biotechnology company focused on cancer therapeutics, announced that CEO James Dentzer will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 10:15 am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Curis, a biotechnology company focused on cancer therapeutics, announced that CEO James Dentzer will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 10:15 am ET. A live webcast will be available on the company's website, with a replay accessible for 90 days. Curis has ongoing collaborations in immuno-oncology, including testing CA-4948 in lymphomas and leukemia, and developing CI-8993 for solid tumors. The company also collaborates with Genentech for Erivedge, a treatment for advanced basal cell carcinoma.
Details
News Market Reaction – CRIS
The recorded move for CRIS in the trading session of this news was -5.64%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., April 6, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 10:15 am ET.
A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com. A replay of the webcast will be available on the Curis website for approximately 90 days following the event.
About Curis, Inc.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination with BTK inhibitor, ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/curis-to-present-at-20th-annual-needham-virtual-healthcare-conference-301262750.html
SOURCE Curis, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.